US EditionWho Is Sanofi's New CEO Belén Garijo?
Belén Garijo will succeed Paul Hudson as Sanofi CEO, aiming to enhance productivity, governance, and R&D innovation; Hudson's tenure saw strategic initiatives over six years.
- On February 12, 2026, Sanofi's Board of Directors appointed Belén Garijo, incoming Chief Executive Officer, following the Appointments Committee proposal.
- Following the Board meeting Wednesday, Sanofi's Board of Directors decided not to renew Paul Hudson's mandate and thanked him for his contributions, as Fr�d�ric Oud�a stated.
- Her résumé shows she spent 15 years at Sanofi, led the Genzyme integration, and served as Vice President of Pharmaceutical Operations for Europe and Canada, and a member of the Sanofi Executive Committee.
- Paul Hudson's last day is set for February 17, 2026, Olivier Charmeil, Executive Vice President, General Medicines, will serve as Interim Chief Executive Officer, and the Board will propose Garijo's candidacy and an articles of association amendment at the April 29, 2026 General Meeting.
- Her priorities include strengthening productivity, governance and R&D, and Belén Garijo, incoming CEO, will accelerate preparation of the Group's future and lead Sanofi's future growth cycle.
52 Articles
52 Articles
The Sanofi board of directors decided to turn the page Paul Hudson. Starting in February, the pharmaceutical group will go through a transition phase, before the arrival of Belén Garijo, who will start a new strategy, focusing on productivity and innovation.
Paul Hudson, head of the pharmaceutical group since 2019, has multiplied the restructuring without succeeding in reviving the laboratory's innovative capacity.
The French pharmaceutical company is replacing its lead. Paul Hudson is followed by Belén Garijo, the former head of Merck. The Sanofi share is therefore falling sharply.
The head of the French pharmaceutical company Sanofi, Paul Hudson, must leave surprisingly. The Supervisory Board did not extend the contract with the British on Thursday, he will leave next week with it. At the end of April Belén Garijo, the former head of the German competitor Merck, as Sanofi announced.The Group thanked Hudson for her "precious contribution", but did not mention any reasons for the change of management.Garijo had already work…
Coverage Details
Bias Distribution
- 43% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
